Invesco’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Invesco’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-24,579	Closed	-$6.24M	–	3774
2020 Q3	$6.24M	Buy	+24,579	New	+$5.03M	﹤0.01%	1901

Other funds holding BCLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco's BCLI Position: Q4 2020 in Review

Invesco sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2020, closing a stake of 24,579 shares — an estimated $6.24M sold.

Invesco first reported a position in BCLI in Q3 2020 and held it in 1 quarter. The position peaked at $6.24M in Q3 2020. 90 funds tracked by Wall St. Rank hold BCLI as of Q4 2020.

Invesco reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2020 after selling out during the quarter.
Invesco sold 24,579 BRAINSTORM CELL THERAPUTC shares in Q4 2020, an estimated $6.24M.
Invesco first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2020 and held it in 1 quarter.
Invesco's BRAINSTORM CELL THERAPUTC position peaked at $6.24M in Q3 2020.
90 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2020.

Based on Invesco's 13F filing for Q4 2020, filed 16 Feb 2021.